v3.26.3
Income Taxes
12 Months Ended
Sep. 30, 2026
Income Tax Disclosure [Abstract]  
Income Taxes

14. Income Taxes

Income before income taxes for all periods presented is from domestic operations, which are the Company’s only operations. During the years ended September 30, 2026, 2025, and 2024, the Company recorded income tax benefit (expense) as follows:

 

 

 

Years Ended September 30,

 

 

 

2026

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Current income tax (expense) benefit:

 

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

1,772

 

 

$

1,936

 

State

 

 

(40

)

 

 

(112

)

 

 

(193

)

Deferred income tax (expense) benefit:

 

 

 

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

 

 

—

 

Income tax (expense) benefit

 

$

(40

)

 

$

1,660

 

 

$

1,743

 

 

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate is as follows:

 

 

 

Years Ended September 30,

 

 

 

 

2026

 

 

2025

 

 

2024

 

 

 

 

Amount

 

 

Percent

 

 

Amount

 

 

Percent

 

 

Amount

 

 

Percent

 

 

 

 

(in thousands, except percentages)

 

 

U.S. federal statutory income tax rate

 

$

14,324

 

 

 

(21.0

)

%

$

17,545

 

 

 

(21.0

)

%

$

24,736

 

 

 

(21.0

)

%

State and local income taxes, net of federal income tax effect

 

 

(262

)

 

 

0.4

 

 

 

(88

)

 

 

0.1

 

 

 

(37

)

 

 

—

 

 

Tax credits

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development tax credits

 

 

3,069

 

 

 

(4.5

)

 

 

4,135

 

 

 

(4.9

)

 

 

2,611

 

 

 

(2.2

)

 

Changes in valuation allowance

 

 

(15,939

)

 

 

23.4

 

 

 

(14,407

)

 

 

17.2

 

 

 

(20,961

)

 

 

17.8

 

 

Nontaxable or nondeductible items

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

(1,169

)

 

 

1.7

 

 

 

(7,031

)

 

 

8.4

 

 

 

(5,880

)

 

 

5.0

 

 

Other

 

 

(46

)

 

 

0.1

 

 

 

(63

)

 

 

0.1

 

 

 

(70

)

 

 

0.1

 

 

Changes in unrecognized tax benefits

 

 

(12

)

 

 

—

 

 

 

(12

)

 

 

—

 

 

 

(6

)

 

 

—

 

 

Interest on net operating loss carryback claim

 

 

—

 

 

 

—

 

 

 

1,594

 

 

 

(1.9

)

 

 

1,450

 

 

 

(1.3

)

 

Other adjustments

 

 

(5

)

 

 

—

 

 

 

(13

)

 

 

—

 

 

 

(100

)

 

 

0.1

 

 

Effective income tax rate

 

$

(40

)

 

 

0.1

 

%

$

1,660

 

 

 

(2.0

)

%

$

1,743

 

 

 

(1.5

)

%

 

The effective tax rates during the years ended September 30, 2026 and 2025 differ from the U.S. federal statutory rate primarily due to the full valuation allowance maintained on the Company’s net deferred tax assets. The state and local income tax component of the effective tax rate reconciliation was primarily attributable to Massachusetts.

 

Changes in the valuation allowance for deferred tax assets during the years ended September 30, 2026, 2025, and 2024 are as follows:

 

 

 

Years Ended September 30,

 

 

 

2026

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Valuation allowance, beginning of year

 

$

(142,233

)

 

$

(127,244

)

 

$

(115,120

)

Increase recorded to valuation allowance

 

 

(17,272

)

 

 

(14,989

)

 

 

(12,124

)

Valuation allowance, end of year

 

$

(159,505

)

 

$

(142,233

)

 

$

(127,244

)

 

Net deferred tax assets as of September 30, 2026 and 2025 consisted of the following:

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

(in thousands)

 

Deferred tax assets:

 

 

 

 

 

 

Capitalized research and development

 

$

47,919

 

 

$

58,675

 

Liability related to the sale of future royalties

 

 

25,537

 

 

 

29,787

 

Tax credit carryforwards

 

 

28,122

 

 

 

24,196

 

Share-based compensation

 

 

12,112

 

 

 

12,911

 

Operating lease liability

 

 

11,499

 

 

 

12,229

 

Net operating loss carryforward

 

 

43,971

 

 

 

14,782

 

Accrued compensation

 

 

925

 

 

 

1,209

 

Accrued expenses

 

 

114

 

 

 

288

 

Other temporary differences

 

 

124

 

 

 

140

 

Total deferred tax assets

 

 

170,323

 

 

 

154,217

 

Valuation allowance

 

 

(159,505

)

 

 

(142,233

)

Net deferred tax assets

 

 

10,818

 

 

 

11,984

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease, right-of-use assets

 

 

(7,402

)

 

 

(7,885

)

Depreciation

 

 

(3,389

)

 

 

(3,920

)

Prepaid expenses

 

 

(152

)

 

 

(170

)

Unrealized loss (gain)

 

 

125

 

 

 

(9

)

Total deferred tax liabilities

 

 

(10,818

)

 

 

(11,984

)

Net deferred income tax assets (liabilities)

 

$

—

 

 

$

—

 

 

As of September 30, 2026, the Company had federal net operating loss carryforwards of $196,293, which do not expire, and state net operating loss carryforwards of $43,550, which may be available to offset future taxable income and expire at various dates beginning in 2032. As of September 30, 2026, the Company also had federal and state research and development tax credit carryforwards of $21,111 and $9,053, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2042 and 2035, respectively.

Utilization of the federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that may have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development tax credit carryforwards that can be utilized annually to offset future tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of 5% stockholders in the stock of a corporation by more than 50% in the aggregate over a three-year period. The Company completed a review of the changes in ownership through September 30, 2022 and determined that the transactions have not resulted in an ownership change during the year ended September 30, 2022, as defined by Section 382. The impact of historical ownership changes has been reflected within the Company's deferred tax assets shown in the table above. Although the Company believes that these ownership changes have not resulted in material limitations on its ability to use these net operating losses and credit carryforwards, its ability to utilize these and future net operating losses and credit carryforwards may be limited due to future ownership changes or for other reasons. As a result, the Company may not be able to take full advantage of its carryforwards for U.S. federal and state tax purposes.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which are comprised primarily of capitalized research and development costs, net operating loss carryforwards and research and development tax credit carryforwards. The Company considers it more likely than not that it will not have sufficient taxable income in the future that will allow it to realize all of its existing deferred tax assets. This is due to the fact the Company continues to progress its wholly-owned research and development programs and its declining royalty revenues from the AbbVie Agreement. As a result, the Company continued to record a valuation allowance as of September 30, 2026 against its deferred tax assets to reduce a portion of the Company’s deferred tax assets for which the Company does not believe it is more likely than not these will be realized.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company’s tax years in the U.S. are still open under statute from 2022 to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. During the year ended September 30, 2024, the Company received notice of examination by the Internal Revenue Service (“IRS”) for the years ending September 30, 2018 and September 30, 2019. The Company received and agreed to a notice of proposed adjustment from the IRS in October 2024, resulting in an additional refund of $871 related to the year ended September 30, 2019. The Company has not received notice of examination by any other jurisdictions for any other tax year open under statute.

Uncertain tax positions represent tax positions for which reserves have been established. The Company’s policy is to record interest and penalties related to uncertain tax positions as part of income tax expense. Total interest related to uncertain tax positions recorded as a liability on the Company’s consolidated balance sheets were $41 and $26 as of September 30, 2026 and 2025, respectively. A reconciliation of the beginning and ending amount of uncertain tax positions is summarized as follows:

 

 

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

(in thousands)

 

Beginning Balance

 

$

892

 

 

$

905

 

Additions based on tax positions for the current period

 

 

—

 

 

 

—

 

Reductions for tax positions due to lapse of statute of limitations

 

 

(10

)

 

 

(13

)

Additions (reductions) for tax positions of prior periods

 

 

—

 

 

 

—

 

Ending Balance

 

$

882

 

 

$

892

 

 

The Company does not expect that its uncertain tax position will materially change within the next twelve months.

 

On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act, which includes several changes to U.S. federal income tax law, including the temporary and permanent extension of expiring provisions of the Tax Cuts and Jobs Act of 2017, such as 100% bonus depreciation and immediate expensing of domestic research and development costs. The new legislation has multiple effective dates, with certain provisions effective in 2025 and others in the future. The Company determined that the tax provisions of the legislation do not have a material impact on its 2026 and 2025 consolidated financial statements and continues to assess the impact on future years.